Cutaneous Melanoma
Authored by James Larkin, published on 2026-03-24 03:17:44.0
Cutaneous Melanoma treatment algorithm by Breslow thickness and stage.
<0.8mm Breslow thickness
Excise and Dermatology FU
>0.8mm Breslow thickness
Excise and discuss SNB
>1mm SN burden: US surveillance and discuss adjuvant systemic Rx: D+T (if BRAF mutant) vs anti-PD1
<1mm SN burden: US surveillance and Dermatology FU
Palpable Stage 3 melanoma
Discuss neoadjuvant / adjuvant pembro or nivo3 + ipi1
Stage 4 melanoma / unresectable Stage 3
Discuss nivo1 + ipi3 or nivo + rela; anti-PD1 monotherapy only if not suitable for combination
Lifileucel if suitable; if BRAF mutant then BRAF targeted therapy can be considered before or after
Stage 4 NED
Discuss anti-PD1 monotherapy, nivo/rela and nivo1 + ipi3
Lifileucel if suitable; if BRAF mutant then BRAF targeted therapy can be considered before or after
For T2b and higher node negative tumors (Stage IIB, IIC), consider adjuvant anti-PD1
tos
privacy